Endothelial dysfunction in diabetes: Potential application of circulating markers as advanced diagnostic and prognostic tools

EPMA Journal

Volumn 1, Issue 1, 2010, Pages 32-45

  Abebe, Worku ^a   Mozaffari, Mahmood ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Circulating markers; Endothelial associated diagnostic; Improved technology limitations; Insulin resistance; Prognostic tools; Vascular disease

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; N(G),N(G) DIMETHYLARGININE; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ARTICLE; CELL PROLIFERATION; CLINICAL ASSESSMENT; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HUMAN; MOLECULAR DYNAMICS; NON INVASIVE PROCEDURE; PLETHYSMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RISK FACTOR;

EID: 79953042781     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0012-7     Document Type: Article

References (69)

1. World Health Organization, www.who.int/mediacentre/factsheets/fs312/en/print.html
2. American Diabetes Association, www.diabetes.org
3. Korc M. Update on diabetes mellitus. Disease Markers. 2004;20:161-5.
4. Kumar V, Abbas A, Fausto N. The endocrine pancreas. In: Robbins and Cotran editors. Pathological Basis of Disease. 7th ed. Elsevier Saunders; 2003.
5. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet. 1962;14:353-62.
6. Hartz AJ, Rupley DC, Kalkhoff RD, et al. Relationship of obesity to diabetes: influence of obesity level and body fat distribution. Prev Med. 1983;12:351-7.
7. Ragland HSP, Leung RW DR, et al. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med. 1991;325:147-52.
8. Kriska AM, Bennett PH. An epidemiological perspective of the relationship between physical activity and NIDDM: from activity assessment to intervention. Diabetes Metab Rev. 1992;8:355-72.
9. Martin JH, Mangiafico S, Kelly DJ. Role of statins in diabetes complications. Curr Diabetes Rev. 2009;5:165-70.
10. Ulrich B. Diabetes and kidney disease. Nephrol Nurs J. 2009;36:461.
11. Cooper ME, Bonnet F, Oldfield M, et al. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertension. 2001;14:475-86.
12. Potenza MA, Gagliardi S, Nacci C, et al. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem. 2009;16:94-112.
13. UK prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. The Lancet. 1998;352:837-53.
14. Koehn J, Tirhani D, krapfenbauer K. Potential predictive biomarkers for the dysfunction of β-cell in type 2 diabetes. In Predictive diagnostic and Personalized treatment, Nova Scientific publishers, Inc.; 2009. p. 183-212
15. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond). 2005;109:143-59.
16. Fitzgerald SM, Brands MW. Nitric oxide may be required to prevent hypertension at the onset of diabetes. Am J Physiol Endocrinol Metab. 2000;279:E762-8.
17. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: part I. Circulation. 2003;108:1917-23.
18. Szmitko PE, Wang CH, Weisel RD, et al. Biomarkers of vascular disease linking inflammation to endothelial activation: part II. Circulation. 2003;108:2041-8.
19. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-6.
20. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J. 1989;3:2007-18.
21. Zhang J, Xie Z, Dong Y, et al. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J Biol Chem. 2008;283:27452-61.
22. Nathanson D, Nyström T. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium. Mol Cell Endocrinol. 2009;297(1-2):112-26.
23. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol. 1999;31(1):61-74.
24. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105(5):546-9.
25. Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res. 1999;43:532-41.
26. Furchgott RF. The 1996 Albert Lasker medical research awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA. 1996;276:1186-8.
27. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001;22:36-52.
28. Tesfamariam B, Jakubowski JA, Cohen RA. Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TxA2. Am J Physiol. 1989;257:H1327-33.
29. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol. 1997;20(11 Suppl 2):11-7.
30. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.
31. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol. 1992;263: H321-6.
32. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res. 2003;11:1278-89.
33. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963-74.
34. Andrews KL, Pannirselvam M, Anderson TJ, et al. The vascular endothelium in diabetes: a practical target for drug treatment? Expert Opin Ther Targets. 2005;9:101-17.
35. Baumgartner-Parzer SM, Wagner L, Pettermann M, et al. Highglucose- triggered apoptosis in cultured endothelial cells. Diabetes. 1995;44:1323-7.
36. McGinn S, Saad S, Poronnik P, et al. High-glucose-mediated effects on endothelial cell proliferation occur via p38 MAP kinase. Am J Physiol. 2003;285:E708-17.
37. Graier WF, Grubenthal I, Dittrich P, et al. Intracellular mechanism of high D-glucose-induced modulation of vascular cell proliferation. Eur J Pharmacol. 1995;294:221-9.
38. Mozaffari MS, Abdelsayed R, Schaffer SW. Diabetic complications: pathogenic mechanisms and prognostic indicators. In: Golubnitschaja O, editor. Predictive diagnostics and personalized treatment: dream or reality? New York: Nova Science Publishers; 2009.
39. Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-7904.
40. Bakker W, Eringa EC, Sipkema P, et al. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res. 2009;335:165-89.
41. Kofler S, Nickel T, Weis M. The role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond). 2005;108:205-13.
42. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003;14:137-45.
43. Raitakari OT, Celermajer DS. Testing for endothelial dysfunction. Ann Med. 2000;32:293-304.
44. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285-95.
45. Goligorsky MS. Clinical assessment of endothelial dysfunction: combine and rule. Curr Opin Nephrol Hypertens. 2006;15:617-24.
46. Münzel T, Sinning C, Post F, et al. Pathophysiology diagnosis and prognostic implications of endothelial dysfunction. Ann Med. 2008;40:180-96.
47. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3:853-76.
48. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828):1111-5.
49. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235-41.
50. Bots ML, Westerink J, Rabelink TJ, et al. Assessment of flowmediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J. 2005;26:363-8.
51. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial artery reactivity task force; International Brachial artery reactivity task force. J Am Coll Cardiol. 2002;39:257-265. Erratum in: J Am Coll Cardiol (2002) 39:1082.
52. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta. 2006;368:33-47.
53. Ding H, Triggle CR. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag. 2005;1:55-71.
54. Salomaa V, Stinson V, Kark JD, et al. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study. Atherosclerosis risk in communities study. Circulation. 1995;91(2):284-90.
55. Benameur T, Andriantsitohaina R, Martínez MC. Therapeutic potential of plasma membrane-derived microparticles. Pharmacol Rep. 2009;61:49-57.
56. Sabatier F, Camoin-Jau L, Anfosso F, et al. Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence. J Cell MolMed. 2009;13:454-71.
57. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta. 2006;373:17-26.
58. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007.
59. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res. 2000;86:1198-202.
60. Balligand JL, Feron O, Dessy C. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiol Rev. 2009;89:481-534.
61. Maclauchlan S, Skokos EA, Agah A, et al. Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and -9, and soluble VEGF. J Histochem Cytochem. 2009; 57:301-13.
62. Lee LC, Chen CS, Choong PF et al. Time-dependent dynamic mobilization of circulating progenitor cells during percutaneous coronary intervention in diabetics. Int. J. cardiology Jan 19. 2009; [Epub ahead of print].
63. Vöö S, Dunaeva M, Eggermann J, et al. Diabetes mellitus impairs CD133+ progenitor cell function after myocardial infarction. J Intern Med. 2009;265:238-49.
64. Hu CH, Li ZM, ZM DU, et al. Human umbilical cord-derived EPCs promote growth cytokines-mediated neorevascularization in rat myocardial infarction. Chin Med J (Engl). 2009;122:548-55.
65. Seandel M, Butler J, Lyden D, et al. Catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. Cancer Cell. 2008;13:181-3.
66. Yao EH, Fukuda N, Matsumoto T, et al. Effects of the antioxidative beta-blocker celiprolol on endothelial progenitor cells in hypertensive rats. Am J Hypertens. 2008;21:1062-8.
67. Wu X, Wang K, Cui L, et al. Effect of granulocyte-colony stimulating factor on the repair of balloon-injured arteries. Pathology. 2008;40:513-9.
68. Rousseau A, Ayoubi F, Deveaux C et al. Impact of age and gender interaction on circulating endothelial progenitor cells in healthy subjects. Fertil Steril Dec 24. 2008; [Epub ahead of print].
69. Xiao Q, Xu Q. Caspase-8: a double-edged sword for EPC functioning. Arterioscler Thromb Vasc Biol. 2009;29:444-6.